Methodologies in Biosimilar Product Development (Chapman & Hall/CRC Biostatistics Series)

ISBN 10: 0367896346 / ISBN 13: 9780367896348

Verlag: Chapman and Hall/CRC, 2021

Beschreibung

Open Books is a nonprofit social venture that provides literacy experiences for thousands of readers each year through inspiring programs and creative capitalization of books.

Bestandsnummer des Verkäufers mon0000728858

Bibliografische Details

• Titel: Methodologies in Biosimilar Product Development (Chapman & Hall/CRC Biostatistics Series)
• Verlag: Chapman and Hall/CRC
• Erscheinungsjahr: 2021
• Sprache: Englisch
• ISBN-10: 0367896346
• ISBN-13: 9780367896348
• Einband: hardcover
• Zustand: Fine

Über diesen Titel

Inhaltsangabe

Methodologies for Biosimilar Product Development covers the practical and challenging issues that are commonly encountered during the development, review, and approval of a proposed biosimilar product. These practical and challenging issues include, but are not limited to the mix-up use of interval hypotheses testing (i.e., the use of TOST) and confidence interval approach, a risk/benefit assessment for non-inferiority/similarity margin, PK/PD bridging studies with multiple references, the detection of possible reference product change over time, design and analysis of biosimilar switching studies, the assessment of sensitivity index for assessment of extrapolation across indications without collecting data from those indications not under study, and the feasibility and validation of non-medical switch post-approval.

Key Features:

• Reviews withdrawn draft guidance on analytical similarity assessment.
• Evaluates various methods for analytical similarity evaluation based on FDA's current guidelines.
• Provides a general approach for the use of n-of-1 trial design for assessment of interchangeability.
• Discusses the feasibility and validity of the non-medical switch studies.
• Provides innovative thinking for detection of possible reference product change over time.

This book embraces innovative thinking of design and analysis for biosimilar studies, which are required for review and approval of biosimilar regulatory submissions.

Über die Autorin bzw. den Autor

Sang Joon Lee, Ph.D., is a Senior Executive Vice President at Celltrion, inc. Dr. Lee was previously an assistant Professor at the University of New Mexico School of Medicine, and a Research Associate and Statistical Analyst at The University of Texas, M.D. Anderson Cancer Center. He received the B.S. degree in Statistics from Inha University, the M.S. degree in Statistics from the Seoul National University, and the Ph.D. degree in Statistics from Texas A&M University. Dr. Lee has authored or co-authored over 100 research papers and invited papers.

Shein-Chung Chow, Ph.D., is a Professor at Duke University School of Medicine. Dr. Chow was previously the Associate Director at the Office of Biostatistics, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA). Dr. Chow has also held various positions in the pharmaceutical industry such as Vice President at Millennium, Executive Director at Covance, and Director and Department Head at Bristol-Myers Squibb. He received the B.S. degree in mathematics from East China Normal University, and the Ph.D. degree in Statistics from the University of Wisconsin-Madison. Dr. Chow has authored or co-authored over 310 methodology papers and 31 books.